Roles of Microvesicles in Tumor Progression and Clinical Applications

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2021 Oct 27

PMID 34703228

Citations 26

Authors

Shuangli Zhu

Shiyu Li

Ming Yi

Ning Li

Kongming Wu

Affiliations

Soon will be listed here.

Abstract

Microvesicles are extracellular vesicles with diameter ranging from 100 to 1000 nm that are secreted by tumor cells or other cells in the tumor microenvironment. A growing number of studies demonstrate that tumor-derived microvesicles are involved in tumor initiation and progression, as well as drug resistance. In addition, tumor-derived microvesicles carry a variety of immunogenic molecules and inhibit tumor response to immunotherapy; therefore, they can be exploited for use in tumor vaccines. Moreover, because of their high stability, tumor-derived microvesicles extracted from body fluids can be used as biomarkers for cancer diagnosis or assessment of prognosis. Tumor-derived microvesicles can also be deployed to reverse drug resistance of tumor regenerative cells, or to deliver chemotherapeutic drugs and oncolytic adenovirus for the treatment of cancer patients. This review summarizes the general characteristics of tumor-derived microvesicles, focusing on their biological characteristics, their involvement in tumor progression, and their clinical applications.

Citing Articles

Approaches and Challenges in Characterizing the Molecular Content of Extracellular Vesicles for Biomarker Discovery.

Kumari S, Lausted C, Scherler K, Ng A, Lu Y, Lee I Biomolecules. 2025; 14(12.

PMID: 39766306 PMC: 11674167. DOI: 10.3390/biom14121599.

Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy.

Yang M, Zhou J, Lu L, Deng D, Huang J, Tang Z Exploration (Beijing). 2024; 4(6):20230171.

PMID: 39713208 PMC: 11655317. DOI: 10.1002/EXP.20230171.

Targeting capabilities of engineered extracellular vesicles for the treatment of neurological diseases.

Yang X, Gao X, Jiang X, Yue K, Luo P Neural Regen Res. 2024; 20(11):3076-3094.

PMID: 39435635 PMC: 11881733. DOI: 10.4103/NRR.NRR-D-24-00462.

Extracellular Vesicles & Co.: scaring immune cells in the TME since ever.

Rodolfo C, Campello S Front Immunol. 2024; 15:1451003.

PMID: 39267748 PMC: 11390669. DOI: 10.3389/fimmu.2024.1451003.

Extracellular vesicles in endometriosis: role and potential.

Chu X, Hou M, Li Y, Zhang Q, Wang S, Ma J Front Endocrinol (Lausanne). 2024; 15:1365327.

PMID: 38737555 PMC: 11082332. DOI: 10.3389/fendo.2024.1365327.

References

Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer S . Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles. PLoS One. 2014; 9(4):e95983. PMC: 3994111. DOI: 10.1371/journal.pone.0095983. View

Szajnik M, Czystowska M, Szczepanski M, Mandapathil M, Whiteside T . Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010; 5(7):e11469. PMC: 2908536. DOI: 10.1371/journal.pone.0011469. View

El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Gieseler F, Plattfaut C, Quecke T, Freund A, Ungefroren H, Ender F . Heterogeneity of microvesicles from cancer cell lines under inflammatory stimulation with TNF-α. Cell Biol Int. 2018; 42(11):1533-1544. DOI: 10.1002/cbin.11040. View

Akao Y, Iio A, Itoh T, Noguchi S, Itoh Y, Ohtsuki Y . Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther. 2010; 19(2):395-9. PMC: 3034851. DOI: 10.1038/mt.2010.254. View

Parenky A, Akalkotkar A, Mulla N, DSouza M . Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine. Vaccine. 2019; 37(41):6085-6092. DOI: 10.1016/j.vaccine.2019.08.033. View

West N, McCuaig S, Franchini F, Powrie F . Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015; 15(10):615-29. DOI: 10.1038/nri3896. View

Yu S, Liu Q, Han X, Qin S, Zhao W, Li A . Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. Exp Hematol Oncol. 2017; 6:31. PMC: 5704598. DOI: 10.1186/s40164-017-0091-4. View

10.

Osterud B . The role of platelets in decrypting monocyte tissue factor. Semin Hematol. 2001; 38(4 Suppl 12):2-5. DOI: 10.1016/s0037-1963(01)90139-8. View

11.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

12.

Dolo V, Ginestra A, Cassara D, Violini S, Lucania G, Torrisi M . Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 1998; 58(19):4468-74. View

13.

Moller A, Lobb R . The evolving translational potential of small extracellular vesicles in cancer. Nat Rev Cancer. 2020; 20(12):697-709. DOI: 10.1038/s41568-020-00299-w. View

14.

Martins V, Dias M, Hainaut P . Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol. 2012; 25(1):66-75. DOI: 10.1097/CCO.0b013e32835b7c81. View

15.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L . Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67(7):2912-5. DOI: 10.1158/0008-5472.CAN-07-0520. View

16.

Zhong W, Ren J, Xiong X, Man Q, Zhang W, Gao L . Increased salivary microvesicles are associated with the prognosis of patients with oral squamous cell carcinoma. J Cell Mol Med. 2019; 23(6):4054-4062. PMC: 6533497. DOI: 10.1111/jcmm.14291. View

17.

Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M . Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006; 56(7):359-67. DOI: 10.1111/j.1440-1827.2006.01972.x. View

18.

Chen G, Zhu J, Zhang Z, Zhang W, Ren J, Wu M . Transformation of cell-derived microparticles into quantum-dot-labeled nanovectors for antitumor siRNA delivery. Angew Chem Int Ed Engl. 2014; 54(3):1036-40. DOI: 10.1002/anie.201410223. View

19.

He W, Calore F, Londhe P, Canella A, Guttridge D, Croce C . Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014; 111(12):4525-9. PMC: 3970508. DOI: 10.1073/pnas.1402714111. View

20.

Dolo V, DAscenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A . Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis. 1999; 17(2):131-40. DOI: 10.1023/a:1006500406240. View